|
| 31411981 | Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. | Eur Urol Oncol | 2021 |
| 32647353 | The intraprostatic immune environment after stereotactic body radiotherapy is dominated by myeloid cells. | Prostate Cancer Prostatic Dis | 2021 |
| 30992160 | Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. | Eur Urol | 2020 |
| 31718822 | Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. | Eur Urol | 2020 |
| 31881546 | Quantification of fiducial marker visibility for MRI-only prostate radiotherapy simulation. | Phys Med Biol | 2020 |
| 32388444 | Dosimetric predictors of patient-reported toxicity after prostate stereotactic body radiotherapy: Analysis of full range of the dose-volume histogram using ensemble machine learning. | Radiother Oncol | 2020 |
| 32562839 | Phase 1 Trial of Stereotactic Body Radiation Therapy Neoadjuvant to Radical Prostatectomy for Patients With High-Risk Prostate Cancer. | Int J Radiat Oncol Biol Phys | 2020 |
| 32373529 | Clinical Assessment of Prostate Displacement and Planning Target Volume Margins for Stereotactic Body Radiotherapy of Prostate Cancer. | Front Oncol | 2020 |
| 32509582 | Development and Validation of a Comprehensive Multivariate Dosimetric Model for Predicting Late Genitourinary Toxicity Following Prostate Cancer Stereotactic Body Radiotherapy. | Front Oncol | 2020 |
| 30326032 | Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis. | JAMA Oncol | 2019 |
| 31673667 | Association between Long-Term Second Malignancy Risk and Radiation: A Comprehensive Analysis of the Entire Surveillance, Epidemiology, and End Results Database (1973-2014). | Adv Radiat Oncol | 2019 |
| 32529134 | Gantry-Mounted Linear Accelerator-Based Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer. | Adv Radiat Oncol | 2019 |
| 31276777 | Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy. | Int J Radiat Oncol Biol Phys | 2019 |
| 30735235 | Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer. | JAMA Netw Open | 2019 |
| 30912957 | Stereotactic body radiotherapy to the prostate and pelvic lymph nodes: A detailed dosimetric analysis of a phase II prospective trial. | Br J Radiol | 2019 |
| 30789399 | Prostate Cancer Pulmonary Metastasis Presenting as a Ground-Glass Pulmonary Nodule on 68Ga-PSMA-11 PET/CT. | Clin Nucl Med | 2019 |
| 31108142 | Testosterone Levels and Sexual Quality of Life After Stereotactic Body Radiation Therapy for Prostate Cancer: A Multi-Institutional Analysis of Prospective Trials. | Int J Radiat Oncol Biol Phys | 2019 |
| 26237192 | Wrong to be Right: Margin Laterality is an Independent Predictor of Biochemical Failure After Radical Prostatectomy. | Am J Clin Oncol | 2018 |
| 30043055 | Optimal Treatment for High-Risk Prostate Cancer-Reply. | JAMA | 2018 |
| 29976500 | Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. | Int J Radiat Oncol Biol Phys | 2018 |
| 31158076 | First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology. | Eur Urol Oncol | 2018 |
| 28301348 | Discord Among Radiation Oncologists and Urologists in the Postoperative Management of High-Risk Prostate Cancer. | Am J Clin Oncol | 2018 |
| 29509865 | Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. | JAMA | 2018 |
| 29653978 | Potential Impact of <sup>68</sup>Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. | J Nucl Med | 2018 |
| 29123013 | <sup>68</sup>Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. | J Nucl Med | 2018 |
| 28537990 | Impact of the Primary Information Source Used for Decision Making on Treatment Perceptions and Regret in Prostate Cancer. | Am J Clin Oncol | 2018 |
| 26535994 | Whole Versus Partial Bladder Radiation: Use of an Image-guided Hypofractionated IMRT Bladder-preservation Protocol. | Am J Clin Oncol | 2018 |
| 27560157 | Does Specialty Bias Trump Evidence in the Management of High-risk Prostate Cancer? | Am J Clin Oncol | 2018 |
| 27322703 | A Pooled Analysis of Biochemical Failure in Intermediate-risk Prostate Cancer Following Definitive Stereotactic Body Radiotherapy (SBRT) or High-Dose-Rate Brachytherapy (HDR-B) Monotherapy. | Am J Clin Oncol | 2018 |
| 27452951 | Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. | Eur Urol | 2017 |
| 30657383 | Use of the Electronic Medical Record to Facilitate Intervention for Patients With Rising Prostate-Specific Antigen Values After Radical Prostatectomy: A Feasibility Study. | JCO Clin Cancer Inform | 2017 |
| 28437208 | Considerations for Quality Improvement in Radiation Oncology Therapy for Patients with Uncomplicated Painful Bone Metastases. | J Palliat Med | 2017 |
| 28168138 | Racial Disparity in Prostate Cancer-Specific Mortality for High-Risk Prostate Cancer: A Population-Based Study. | Cureus | 2017 |
| 28111115 | Reply to Thomas Van den Broeck, R. Jeffrey Karnes, and Steven Joniau's Letter to the Editor re: Amar U. Kishan, Talha Shaikh, Pin-Chieh Wang, et al. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol 2017;71:766-73. | Eur Urol | 2017 |
| 28187996 | Pattern of solid and hematopoietic second malignancy after local therapy for prostate cancer. | Radiother Oncol | 2017 |
| 28126301 | Exploring Value From the Patient's Perspective Between Modern Radiation Therapy Modalities for Localized Prostate Cancer. | Int J Radiat Oncol Biol Phys | 2017 |
| 28178376 | Treatment trends for patients with brain metastases: Does practice reflect the data? | Cancer | 2017 |
| 28807747 | Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy. | Brachytherapy | 2017 |
| 28721887 | External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study. | Int J Radiat Oncol Biol Phys | 2017 |
| 28586966 | In Reply to Scott. | Int J Radiat Oncol Biol Phys | 2017 |
| 28552819 | Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-free Survival in Clinically Localized, Intermediate- and High-risk Prostate Cancer. | Urology | 2017 |
| 28577834 | Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer. | Semin Radiat Oncol | 2017 |
| 27997685 | Urinary toxicity after stereotactic body radiotherapy: The boy who cried wolf? | Cancer | 2017 |
| 27048826 | Re: Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy?: L. J. Sokoll, Z. Zhang, D. W. Chan, A. C. Reese, T. J. Bivalacqua, A. W. Partin and P. C. Walsh J Urol 2016;195:330-336. | J Urol | 2016 |
| 26524087 | Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer. | Cancer | 2016 |
| 27587270 | Plan quality and dosimetric association of patient-reported rectal and urinary toxicities for prostate stereotactic body radiotherapy. | Radiother Oncol | 2016 |
| 27863963 | The dose-response of salvage radiotherapy following radical prostatectomy: A systematic review and meta-analysis. | Radiother Oncol | 2016 |
| 27890426 | Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer. | Radiother Oncol | 2016 |
| 26850649 | SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer. | Pract Radiat Oncol | 2016 |
| 25463990 | Ultrasensitive prostate specific antigen after prostatectomy reliably identifies patients requiring postoperative radiotherapy. | J Urol | 2015 |